News

ENHERTU® (trastuzumab deruxtecan) Receives Time-Limited Reimbursement Recommendation from Canada's Drug Agency for Gastric Cancer
AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation – the first in gastric ...
BioPharma Dive21h
AI tool could help doctors ID breast cancers vulnerable to Enhertu
Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) ...
BioSpace4h
Practice-Changing Data, Innovative Modalities and China in Focus at #ASCO25
Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...
Fierce Pharma1d
AstraZeneca, Merck duke it out at the top of oncologists’ pharma perception ranking
ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...
The Pharma Letter1d
AstraZeneca at plenary again with pivotal ASCO data
UK pharma major AstraZeneca (LSE: AZN) is set to present data from more than 80 studies at the 2025 American Society of ...
pharmaphorum7h
ASCO 25: Roche places Itovebi marker in breast cancer
Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...
The Pharma Letter2d
Big build-up for AstraZeneca’s ASCO offering
Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...
Le Lézard21h
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific ...
Immunotherapy Drugs (Monoclonal Antibodies, Immunomodulators, Vaccine) Market Size, Share & Trends Analysis and Growth Forecasts, 2025-2030
The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...
pharmaphorum1d
EU clears Enhertu for HER2-low breast cancer
The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...
Canadian Manufacturing5h
AstraZeneca and Daiichi Sankyo secure early access deal for ENHERTU
In addition, AstraZeneca, Daiichi Sankyo, and the pan-Canadian Pharmaceutical Alliance (pCPA) have signed a Letter of Intent under the Temporary Access Process (pTAP). Together with the TLR, this ...